M&A Pressure Mounts For Merck & Co After Alzheimer's Drug Dismissed
Merck's verubecestat has flopped in a second Phase III Alzheimer's trial; investors are anticipating M&A or licensing deals soon to bring something new into the big pharma's development portfolio.
You may also be interested in...
Merck Research Laboratories president Roger Perlmutter returned to the company when its R&D was at a crossroads. Now he is retiring and handing the company’s post-Keytruda growth over to SVP Dean Li.
An interim look at two Phase II/III trials showed the drug worsened cognition in people at high risk of developing Alzheimer's disease. This is the 16th failure of a BACE-targeting therapy.
Elenbecestat can continue in the Phase III MISSION AD studies in Alzheimer’s, the data safety monitoring board says.